Munich Startup

News & Podcast

Stay up to date with the latest stories, deep-dives and interviews from the Munich startup ecosystem. From funding deals to founder portraits and tech trends.

Format:
Category:
12+ Results (49 total)– filtered by:#Healthtech
Solve for Tomorrow: Ideen gesucht!
competitions

Solve for Tomorrow: Ideen gesucht!

Apply now: Solve for Tomorrow is looking for ideas in the areas of health, sustainability, and social inclusion. The application deadline for the funding program runs until June 23, 2026.

Saskia Müller
S. Müller
30.05.26
2 Min.
Fresenius invests in Munich healthtech startup Avelios Medical
Deals

Fresenius invests in Munich healthtech startup Avelios Medical

Fresenius is joining Avelios Medical and thus expanding the technology partnership between the Munich healthtech startup and SAP that launched in February. The goal is to build an open, interoperable, and AI-native digital healthcare ecosystem for Europe. The core platform is the Avelios hospital information system.

Bernd Heppel
B. Heppel
12.05.26
3 Min.
Rnatics: Hope in pulmonary fibrosis
Interviews

Rnatics: Hope in pulmonary fibrosis

Rnatics is developing RCS-21, a novel inhalable drug against lung inflammation and idiopathic pulmonary fibrosis. The startup was founded in 2021 as a spin-off from TUM by Stefan Engelhardt together with Thomas Frischmuth and Klaus Rabe. After promising research and ongoing clinical studies, the team aims to reach the next milestones and create new therapy options for patients. Clinical lead and pharmacist with a PhD, Christina Beck, explains the details about the founding and mission to us.

Saskia Doll
S. Doll
17.04.26
2 Min.
Tubulis acquired by American pharma giant
Deals

Tubulis acquired by American pharma giant

Munich-based biotech unicorn Tubulis is being acquired by US company Gilead for a multibillion-euro amount.

Saskia Doll
S. Doll
10.04.26
3 Min.
Rnhale: Inhalable RNA for new therapies
Interviews

Rnhale: Inhalable RNA for new therapies

The Munich-based biotech startup Rnhale develops inhalable RNA therapeutics as dry powder – faster, simpler, and more efficient than previous approaches. This is intended to treat respiratory diseases such as COPD or asthma in a targeted manner. CEO Benjamin Winkeljann explains in an interview why the path from research to product is challenging and what hurdles almost caused them to fail.

Saskia Doll
S. Doll
23.03.26
4 Min.
Mpiriq: AI connects healthcare and research
Interviews

Mpiriq: AI connects healthcare and research

Mpiriq connects medical healthcare and research using artificial intelligence. The platform structures data from practices and hospitals, automates documentation and thus enables faster studies and better therapies – without additional effort in daily work. The team explains how it works and why trust is crucial in an interview.

Saskia Doll
S. Doll
20.03.26
5 Min.
SAP invests in Avelios Medical
Deals

SAP invests in Avelios Medical

Munich-based software provider Avelios Medical receives a strategic investment from SAP. Together, the partners are developing a new digital platform for hospitals, responding to the planned replacement of central IT systems in the clinical market.

Saskia Doll
S. Doll
05.03.26
3 Min.
Milestone in treating lung disease? Rnatics secures €2.7 million
Deals

Milestone in treating lung disease? Rnatics secures €2.7 million

The Munich biotech startup Rnatics secures €2.7 million in federal funding. The funds will support clinical development of an inhalable RNA therapeutic for inflammatory and fibrotic lung diseases.

Saskia Doll
S. Doll
04.03.26
2 Min.
Custom Surgical raises funding for digitalization of ophthalmology
Deals

Custom Surgical raises funding for digitalization of ophthalmology

Munich-based medtech startup Custom Surgical receives 3.5 million euros from Ventech, Zeiss, and other investors. With the pre-Series A round, the company is advancing the digitalization of workflows in ophthalmology and its international expansion.

Saskia Doll
S. Doll
24.02.26
2 Min.
Smartbax: New antibiotics against superbugs
Interviews

Smartbax: New antibiotics against superbugs

Smartbax develops innovative antibiotics against multidrug-resistant bacteria with a completely new mechanism of action: instead of blocking processes, they cause pathogens to self-destruct. Emerging from research at TU München, the startup is working on clinical trials while fighting against the resistance crisis and market hurdles.

Saskia Doll
S. Doll
09.02.26
7 Min.
Bodyfast secures strategic investment
Deals

Bodyfast secures strategic investment

Munich-based healthtech Bodyfast is securing its first strategic investor with Isartal Health Media. The investment by Wort & Bild publishing group marks the next growth milestone for the intermittent fasting app.

Saskia Doll
S. Doll
27.01.26
2 Min.
Cellbyte: AI accelerates market access for pharma
Interviews

Cellbyte: AI accelerates market access for pharma

Cellbyte wants to revolutionize the global market launch of medicines: with an AI-native platform, the Munich startup automates pricing and market access processes in the pharmaceutical industry. Over 100 data sources, deep industry knowledge, and regulatory expertise enable complex decisions in seconds.

Saskia Doll
S. Doll
12.01.26
4 Min.